Skip to content
Open access

A Retrospective Study of the Efficacy and Safety of Chemoimmunotherapy in Elderly Patients with Extensive-Stage Small Cell Lung Cancer

Sep 2026 · Cancers · Vol 18 · 0 citations · 33 references
Medicine

Abstract

Simple Summary This retrospective study evaluated the effectiveness and safety of adding a programmed death-ligand 1 (PD-L1) inhibitor to platinum-based chemotherapy in patients aged ≥75 year with extensive-stage small cell lung cancer. The combination treatment significantly prolonged overall survival compared with chemotherapy alone. The incidence of severe adverse events was comparable between patients aged ≥75 years and younger patients. These findings suggest that adding a PD-L1 inhibitor to chemotherapy appears to be an effective and tolerable first-line treatment option for elderly patients with extensive-stage small cell lung cancer.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.